1. known severe allergic reactions to monoclonal antibodies 2. active tuberculosis (tb) infection 3. history of inadequately treated tuberculosis or latent tuberculosis 4. in the opinion of the investigator,progression to death is highly probable, irrespective of the provision of treatments 5. have received oral anti-rejection or immune-suppressive drugs within the past 6 months 6. participating in other drug clinical trials (participation in covid-19 anti-viral trials may be permitted if approved by medical monitor) 7. pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination 8. patients with known history of hepatitis b, hepatitis c or hiv 9. absolute neutrophils count (anc) \<1000 / mm3 10. platelets \<50,000 / mm3 11. absolute lymphocyte count (alc): \<500/mm3

1. known severe allergic reactions to monoclonal antibodies 2. active tuberculosis (tb) infection 3. history of inadequately treated tuberculosis or latent tuberculosis 4. in the opinion of the investigator,progression to death is highly probable, irrespective of the provision of treatments 5. have received oral anti-rejection or immune-suppressive drugs within the past 6 months 6. participating in other drug clinical trials (participation in covid-19 anti-viral trials may be permitted if approved by medical monitor) 7. pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination 8. patients with known history of hepatitis b, hepatitis c or hiv 9. absolute neutrophils count (anc) \<1000 / mm3 10. platelets \<50,000 / mm3 11. absolute lymphocyte count (alc): \<500/mm3

known severe allergic reactions to monoclonal antibodies active tuberculosis (tb) infection history of inadequately treated tuberculosis or latent tuberculosis in the opinion of the investigator,progression to death is highly probable, irrespective of the provision of treatments have received oral anti-rejection or immune-suppressive drugs within the past 6 months participating in other drug clinical trials (participation in covid-19 anti-viral trials may be permitted if approved by medical monitor) pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination patients with known history of hepatitis b, hepatitis c or hiv absolute neutrophils count (anc) <1000 / mm3 platelets <50,000 / mm3 absolute lymphocyte count (alc): <500/mm3

known severe allergic reactions to monoclonal antibodies active tuberculosis (tb) infection history of inadequately treated tuberculosis or latent tuberculosis in the opinion of the investigator,progression to death is highly probable, irrespective of the provision of treatments have received oral anti-rejection or immune-suppressive drugs within the past 6 months participating in other drug clinical trials (participation in covid-19 anti-viral trials may be permitted if approved by medical monitor) pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination patients with known history of hepatitis b, hepatitis c or hiv absolute neutrophils count (anc) <1000 / mm3 platelets <50,000 / mm3 absolute lymphocyte count (alc): <500/mm3

1. known severe allergic reactions to monoclonal antibodies 2. active tuberculosis (tb) infection 3. history of inadequately treated tuberculosis or latent tuberculosis 4. in the opinion of the investigator,progression to death is highly probable, irrespective of the provision of treatments 5. have received oral anti-rejection or immune-suppressive drugs within the past 6 months 6. participating in other drug clinical trials (participation in covid-19 anti-viral trials may be permitted if approved by medical monitor) 7. pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination 8. patients with known history of hepatitis b, hepatitis c or hiv 9. absolute neutrophils count (anc) <1000 / mm3 10. platelets <50,000 / mm3 11. absolute lymphocyte count (alc): <500/mm3

1. known severe allergic reactions to monoclonal antibodies 2. active tuberculosis (tb) infection 3. history of inadequately treated tuberculosis or latent tuberculosis 4. in the opinion of the investigator,progression to death is highly probable, irrespective of the provision of treatments 5. have received oral anti-rejection or immune-suppressive drugs within the past 6 months 6. participating in other drug clinical trials (participation in covid-19 anti-viral trials may be permitted if approved by medical monitor) 7. pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination 8. patients with known history of hepatitis b, hepatitis c or hiv 9. absolute neutrophils count (anc) <1000 / mm3 10. platelets <50,000 / mm3 11. absolute lymphocyte count (alc): <500/mm3